loading
前日終値:
$24.94
開ける:
$25.33
24時間の取引高:
113.51K
Relative Volume:
0.81
時価総額:
$646.00M
収益:
-
当期純損益:
$-69.47M
株価収益率:
-4.1967
EPS:
-5.5973
ネットキャッシュフロー:
$-73.92M
1週間 パフォーマンス:
-6.86%
1か月 パフォーマンス:
-1.39%
6か月 パフォーマンス:
+4.54%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
Value
$23.13
$25.34
1週間の範囲:
Value
$23.13
$25.90
52週間の値動き範囲:
Value
$14.42
$38.93

Lenz Therapeutics Inc Stock (LENZ) Company Profile

Name
名前
Lenz Therapeutics Inc
Name
セクター
Healthcare (1169)
Name
電話
858-925-7000
Name
住所
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Name
職員
0
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
LENZ's Discussions on Twitter

LENZ を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
LENZ
Lenz Therapeutics Inc
23.49 646.00M 0 -69.47M -73.92M -5.5973
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.24 124.35B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
700.33 76.56B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
644.48 39.16B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
250.59 32.44B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
BNTX
Biontech Se Adr
120.01 28.77B 3.30B -501.07M 1.03B -2.1146

Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2024-09-27 開始されました Raymond James Outperform
2024-08-12 開始されました H.C. Wainwright Buy
2024-04-15 開始されました Leerink Partners Outperform
2024-04-15 開始されました William Blair Outperform
2024-04-10 開始されました Citigroup Buy
2024-03-27 開始されました Piper Sandler Overweight
2023-02-23 ダウングレード BofA Securities Neutral → Underperform
2023-02-23 ダウングレード Cantor Fitzgerald Overweight → Neutral
2023-02-23 ダウングレード Cowen Outperform → Market Perform
2023-01-25 ダウングレード BTIG Research Buy → Neutral
2023-01-18 ダウングレード BofA Securities Buy → Neutral
2023-01-06 ダウングレード BMO Capital Markets Outperform → Market Perform
2023-01-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2022-09-15 開始されました Cantor Fitzgerald Overweight
2022-06-17 開始されました BMO Capital Markets Outperform
2022-04-14 開始されました BTIG Research Buy
2022-03-22 ダウングレード Morgan Stanley Overweight → Equal-Weight
2022-02-18 開始されました RBC Capital Mkts Sector Perform
2021-07-20 開始されました Morgan Stanley Overweight
2021-07-20 開始されました SVB Leerink Outperform
すべてを表示

Lenz Therapeutics Inc (LENZ) 最新ニュース

pulisher
Feb 21, 2025

LENZ Therapeutics (LENZ) to Release Quarterly Earnings on Wednesday - Defense World

Feb 21, 2025
pulisher
Feb 19, 2025

LENZ Therapeutics Insiders Placed Bullish Bets Worth US$551.1k - Yahoo Finance UK

Feb 19, 2025
pulisher
Feb 18, 2025

Citi maintains Buy on LENZ Therapeutics, target at $44 By Investing.com - Investing.com Canada

Feb 18, 2025
pulisher
Feb 18, 2025

Citi maintains Buy on LENZ Therapeutics, target at $44 - Investing.com

Feb 18, 2025
pulisher
Feb 16, 2025

Mirae Asset Global Investments Co. Ltd. Makes New Investment in ArriVent BioPharma, Inc. (NASDAQ:AVBP) - Defense World

Feb 16, 2025
pulisher
Feb 16, 2025

916 Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Acquired by Mirae Asset Global Investments Co. Ltd. - Defense World

Feb 16, 2025
pulisher
Feb 13, 2025

LENZ Therapeutics (NASDAQ:LENZ) Shares Down 4.7%Should You Sell? - MarketBeat

Feb 13, 2025
pulisher
Feb 10, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Acquired by SG Americas Securities LLC - Defense World

Feb 10, 2025
pulisher
Feb 07, 2025

The Presbyopia Market Size to Reach USD 2,513.0 Million by 2035, Impelled by Technological Advancements in Diagnostic Tools - BioSpace

Feb 07, 2025
pulisher
Feb 07, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Analysts - MarketBeat

Feb 07, 2025
pulisher
Feb 06, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives $35.40 Average Target Price from Brokerages - Defense World

Feb 06, 2025
pulisher
Feb 04, 2025

LENZ Therapeutics (NASDAQ:LENZ) Trading 8% HigherWhat's Next? - MarketBeat

Feb 04, 2025
pulisher
Feb 04, 2025

Leerink Partnrs Has Negative Outlook of LENZ FY2025 Earnings - MarketBeat

Feb 04, 2025
pulisher
Feb 02, 2025

LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5.1%What's Next? - MarketBeat

Feb 02, 2025
pulisher
Feb 01, 2025

LENZ Therapeutics (LENZ) to Release Earnings on Wednesday - MarketBeat

Feb 01, 2025
pulisher
Feb 01, 2025

Leerink Partnrs Has Pessimistic View of LENZ FY2025 Earnings - Defense World

Feb 01, 2025
pulisher
Jan 31, 2025

More Heart, Less Skin: US FDA’s 2025 Novel Approvals Should Reflect Pipeline Shifts - News & Insights

Jan 31, 2025
pulisher
Jan 30, 2025

Yankuang Energy Group Company Limited (OTCMKTS:YZCAY) Sees Large Decrease in Short Interest - Defense World

Jan 30, 2025
pulisher
Jan 29, 2025

Myopia Pipeline 2024: Detailed Clinical Trials - openPR

Jan 29, 2025
pulisher
Jan 29, 2025

LENZ Therapeutics (LENZ) Expected to Announce Earnings on Wednesday - Defense World

Jan 29, 2025
pulisher
Jan 25, 2025

Barclays PLC Sells 1,835 Shares of Grupo Financiero Galicia S.A. (NASDAQ:GGAL) - Defense World

Jan 25, 2025
pulisher
Jan 23, 2025

Presbyopia Market on Track for Major Expansion by 2034, According to DelveInsight - EIN News

Jan 23, 2025
pulisher
Jan 20, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Sees Significant Increase in Short Interest - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

Lincoln Electric Holdings, Inc. (NASDAQ:LECO) Short Interest Down 5.0% in December - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

LifeVantage Co. (NASDAQ:LFVN) Short Interest Down 5.4% in December - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

Lifecore Biomedical, Inc. (NASDAQ:LFCR) Sees Significant Increase in Short Interest - Defense World

Jan 20, 2025
pulisher
Jan 20, 2025

Morgan Stanley Cuts U.S. Bancorp (NYSE:USB) Price Target to $59.00 - Defense World

Jan 20, 2025
pulisher
Jan 19, 2025

Short Interest in LENZ Therapeutics, Inc. (NASDAQ:LENZ) Expands By 11.9% - MarketBeat

Jan 19, 2025
pulisher
Jan 19, 2025

Barclays PLC Has $391,000 Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Jan 19, 2025
pulisher
Jan 19, 2025

Barclays PLC Buys 12,051 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

Jan 19, 2025
pulisher
Jan 17, 2025

LENZ Therapeutics (NASDAQ:LENZ) Trading Down 5%Time to Sell? - MarketBeat

Jan 17, 2025
pulisher
Jan 14, 2025

Trio-Tech International (NYSE:TRT) Coverage Initiated by Analysts at StockNews.com - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

Harbor Capital Advisors Inc. Buys Shares of 43,989 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

Brokerages Set LENZ Therapeutics, Inc. (NASDAQ:LENZ) PT at $35.40 - Defense World

Jan 12, 2025
pulisher
Jan 11, 2025

Jane Street Group LLC Acquires Shares of 12,027 LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World

Jan 11, 2025
pulisher
Jan 10, 2025

LENZ Therapeutics (NASDAQ:LENZ) Shares Down 8.9%Here's What Happened - MarketBeat

Jan 10, 2025
pulisher
Jan 10, 2025

Intellia stock hurts gene editing after layoffs (NTLA:NASDAQ) - Seeking Alpha

Jan 10, 2025
pulisher
Jan 10, 2025

Lenz Therapeutics New Becomes Oversold (LENZ) - Nasdaq

Jan 10, 2025
pulisher
Jan 10, 2025

Financial Survey: Fresh Tracks Therapeutics (NASDAQ:FRTX) vs. LENZ Therapeutics (NASDAQ:LENZ) - Defense World

Jan 10, 2025
pulisher
Jan 10, 2025

Head to Head Contrast: Allied Resources (ALOD) versus Its Peers - Defense World

Jan 10, 2025
pulisher
Jan 09, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Average Rating of "Buy" from Brokerages - MarketBeat

Jan 09, 2025
pulisher
Jan 08, 2025

Sionna Therapeutics Appoints Dr. Marcella Kuhlman Ruddy and Dr. Jo Viney to its Board of Directors - citybiz

Jan 08, 2025
pulisher
Jan 04, 2025

SkyWater Technology, Inc. (NASDAQ:SKYT) Shares Purchased by Barclays PLC - Defense World

Jan 04, 2025
pulisher
Jan 04, 2025

NI Holdings, Inc. (NASDAQ:NODK) Shares Purchased by Barclays PLC - Defense World

Jan 04, 2025
pulisher
Jan 04, 2025

Barclays PLC Acquires 45,781 Shares of Larimar Therapeutics, Inc. (NASDAQ:LRMR) - Defense World

Jan 04, 2025
pulisher
Jan 03, 2025

Geode Capital Management LLC Lowers Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat

Jan 03, 2025
pulisher
Jan 03, 2025

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Geode Capital Management LLC - Defense World

Jan 03, 2025
pulisher
Jan 02, 2025

Neumora plummets on depression drug data - BioPharma Dive

Jan 02, 2025
pulisher
Jan 01, 2025

Companies Like LENZ Therapeutics (NASDAQ:LENZ) Are In A Position To Invest In Growth - Simply Wall St

Jan 01, 2025

Lenz Therapeutics Inc (LENZ) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Lenz Therapeutics Inc (LENZ) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Schimmelpennink Evert B.
President, CEO and Secretary
Jul 22 '24
Option Exercise
1.04
45,000
46,800
45,000
Chevallard Daniel R.
Chief Financial Officer
May 14 '24
Buy
15.68
3,188
49,988
3,188
MCCOLLUM JAMES W
Director
May 13 '24
Buy
15.99
31,332
501,093
525,565
RA CAPITAL MANAGEMENT, L.P.
Director
Mar 21 '24
Buy
15.03
998,009
15,000,075
3,319,339
$33.42
price up icon 0.27%
$81.06
price down icon 3.05%
$361.10
price down icon 1.70%
$22.12
price down icon 4.08%
biotechnology ONC
$255.37
price up icon 4.57%
$120.01
price up icon 1.81%
大文字化:     |  ボリューム (24 時間):